Crossmark

CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer

Crossref DOI link: https://doi.org/10.1007/s00262-018-2250-9

Published Online: 2018-09-26

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jiang, Qi

Fu, Qiang

Chang, Yuan

Liu, Zheng

Zhang, Junyu

Xu, Le

Zhu, Yu

Wang, Yiwei

Zhang, Weijuan

Xu, Jiejie https://orcid.org/0000-0001-7431-9063
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81471621)

National Natural Science Foundation of China (81472227)

National Natural Science Foundation of China (81671628)

National Natural Science Foundation of China (31770851)

National Natural Science Foundation of China (81871306)

National Natural Science Foundation of China (81872082)

the Shanghai Sailing Program (18YF1404500)

Shanghai Municipal Commission of Health and Family Planning Program (20144Y0223)
License Information

Text and Data Mining valid from 2018-09-26
More Information

Article History

Received: 18 January 2018

Accepted: 20 September 2018

First Online: 26 September 2018

Compliance with ethical standards

:

: The authors declare no conflict of interest.

: This study was approved by the institutional ethical review boards of Zhongshan Hospital, Fudan University (Registration no. B2015-030) and Fudan University Shanghai Cancer Center (Registration no. 050432-4-1212B). Written informed consent approved by the institutional ethics committee was obtained from each patient.